Making financial sacrifices during treatment can have long-term effects on survivorship for patients with cancer, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
Making financial sacrifices during treatment can have long-term effects on survivorship for patients with cancer, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
Transcript
In your research, have you discovered trends that indicate which patients fare better after active cancer treatment is completed?
So, in my own research what I focus on often is the experience of cancer patients [who] have comorbid conditions. Also, I’ve done some work with longer-term survivors, and with longer-term survivors, [those] patients who have perceived to have had to make a financial sacrifice during the acute treatment experience can have longer term experiences of distress, psychological distress. So, I think the impact [on] finances at the acute phase can have a really enduring effect on someone’s experience over the long term.
Are payers doing enough to ensure that cancer survivors receive appropriate follow up care, and if not what needs to change?
So, I think that currently the evidence in survivorship is evolving as the population of cancer survivors is growing. I think that as more information is developed about risk stratifications, so which patients have the most complex long-term sequelae. Payers can really incentive providers coordinating that care and providing that care in a way that’s efficient but also effective, and I think that is improving the information evidence is improving over time and I think payers can incentive putting that evidence into practice.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More